Investors/British Patient Capital

7 London Mempool companies backed by British Patient Capital

Rank =37 of 430 on the investor leaderboard. No source we have says it led a round in any of them.

See them on the mapCounts only deals named in a source we fetched

Inner London. Coloured dots are the portfolio, grey dots the rest of the map.

Portfolio by sector

Health44 Health companies
AI11 AI company
Fintech11 Fintech company
Other11 Other company

Portfolio on the map (7)

Quantexa$545M
Decision intelligence software that connects data to spot fraud, financial crime and risk for banks and governments.
AI · Decision Intelligence · Well known
source: clay.com
Purespring Therapeutics£115M
London gene therapy company targeting kidney podocytes to treat diseases such as IgA nephropathy.
Health · Kidney Gene Therapy · Fastest growing
source: purespringtx.com
Proximie$130M
Cloud platform that connects operating rooms so surgeons can collaborate remotely and hospitals can analyse surgical video and data.
Health · Surgical software · Up and coming
source: siliconcanals.com
CyberSmart
CyberSmart gives small businesses cybersecurity tools, staff training, Cyber Essentials certification and cyber insurance in one platform.
Other · Cybersecurity · Up and coming
source: fintech.global
Epsilogen
Develops IgE, IgA and IgG antibody therapeutics for cancer, with lead candidate MOv18 IgE in a Phase Ib trial in platinum-resistant ovarian cancer.
Health · Cancer antibodies · Up and coming
source: samedanltd.com
Form3
Cloud platform that runs account to account payment processing for Tier 1 banks and fintechs, including Nationwide.
Fintech · Payments Infrastructure · Up and coming
source: form3.tech
Quell Therapeutics
Develops engineered CAR-Treg cell therapies for autoimmune disease and organ transplant rejection.
Health · Cell Therapy · Up and coming
source: quell-tx.com

Often alongside

Syncona2 shared

We list British Patient Capital on a company only when a page we fetched names it as an investor. Its real London portfolio is likely bigger. Know a deal we missed? Suggest a fix with a source. How we count